FeLIX is a restriction factor for mammalian retrovirus infection
Retroviruses are unique in using reverse transcriptase to convert RNA genomes into DNA, infecting germ cells, and transmitting to offspring. Numerous ancient retroviral sequences are known as endogenous retroviruses (ERVs). The soluble Env protein derived from ERVs functions as a co-factor that assi...
Saved in:
| Published in | Journal of virology Vol. 98; no. 4; p. e0177123 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
16.04.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Retroviruses are unique in using reverse transcriptase to convert RNA genomes into DNA, infecting germ cells, and transmitting to offspring. Numerous ancient retroviral sequences are known as endogenous retroviruses (ERVs). The soluble Env protein derived from ERVs functions as a co-factor that assists in FeLV-T infection. However, herein, we show that the soluble Env protein exhibits antiviral activity and provides resistance to mammalian retrovirus infection through competitive receptor binding. In particular, this finding may explain why FeLV-B transmission is not observed among domestic cats. ERV-derived molecules can benefit animals in an evolutionary arms race, highlighting the double-edged-sword nature of ERVs. |
|---|---|
| AbstractList | Endogenous retroviruses (ERVs) are remnants of ancestral viral infections. Feline leukemia virus (FeLV) is an exogenous and endogenous retrovirus in domestic cats. It is classified into several subgroups (A, B, C, D, E, and T) based on viral receptor interference properties or receptor usage. ERV-derived molecules benefit animals, conferring resistance to infectious diseases. However, the soluble protein encoded by the defective envelope (
) gene of endogenous FeLV (enFeLV) functions as a co-factor in FeLV subgroup T infections. Therefore, whether the gene emerged to facilitate viral infection is unclear. Based on the properties of ERV-derived molecules, we hypothesized that the defective
genes possess antiviral activity that would be advantageous to the host because FeLV subgroup B (FeLV-B), a recombinant virus derived from enFeLV
, is restricted to viral transmission among domestic cats. When soluble truncated Env proteins from enFeLV were tested for their inhibitory effects against enFeLV and FeLV-B, they inhibited viral infection. Notably, this antiviral machinery was extended to infection with the Gibbon ape leukemia virus, Koala retrovirus A, and Hervey pteropid gammaretrovirus. Although these viruses used feline phosphate transporter 1 (fePit1) and phosphate transporter 2 as receptors, the inhibitory mechanism involved competitive receptor binding in a fePit1-dependent manner. The shift in receptor usage might have occurred to avoid the inhibitory effect. Overall, these findings highlight the possible emergence of soluble truncated Env proteins from enFeLV as a restriction factor against retroviral infection and will help in developing host immunity and antiviral defense by controlling retroviral spread.IMPORTANCERetroviruses are unique in using reverse transcriptase to convert RNA genomes into DNA, infecting germ cells, and transmitting to offspring. Numerous ancient retroviral sequences are known as endogenous retroviruses (ERVs). The soluble Env protein derived from ERVs functions as a co-factor that assists in FeLV-T infection. However, herein, we show that the soluble Env protein exhibits antiviral activity and provides resistance to mammalian retrovirus infection through competitive receptor binding. In particular, this finding may explain why FeLV-B transmission is not observed among domestic cats. ERV-derived molecules can benefit animals in an evolutionary arms race, highlighting the double-edged-sword nature of ERVs. Endogenous retroviruses (ERVs) are remnants of ancestral viral infections. Feline leukemia virus (FeLV) is an exogenous and endogenous retrovirus in domestic cats. It is classified into several subgroups (A, B, C, D, E, and T) based on viral receptor interference properties or receptor usage. ERV-derived molecules benefit animals, conferring resistance to infectious diseases. However, the soluble protein encoded by the defective envelope ( env ) gene of endogenous FeLV (enFeLV) functions as a co-factor in FeLV subgroup T infections. Therefore, whether the gene emerged to facilitate viral infection is unclear. Based on the properties of ERV-derived molecules, we hypothesized that the defective env genes possess antiviral activity that would be advantageous to the host because FeLV subgroup B (FeLV-B), a recombinant virus derived from enFeLV env , is restricted to viral transmission among domestic cats. When soluble truncated Env proteins from enFeLV were tested for their inhibitory effects against enFeLV and FeLV-B, they inhibited viral infection. Notably, this antiviral machinery was extended to infection with the Gibbon ape leukemia virus, Koala retrovirus A, and Hervey pteropid gammaretrovirus. Although these viruses used feline phosphate transporter 1 (fePit1) and phosphate transporter 2 as receptors, the inhibitory mechanism involved competitive receptor binding in a fePit1-dependent manner. The shift in receptor usage might have occurred to avoid the inhibitory effect. Overall, these findings highlight the possible emergence of soluble truncated Env proteins from enFeLV as a restriction factor against retroviral infection and will help in developing host immunity and antiviral defense by controlling retroviral spread. Endogenous retroviruses (ERVs) are remnants of ancestral viral infections. Feline leukemia virus (FeLV) is an exogenous and endogenous retrovirus in domestic cats. It is classified into several subgroups (A, B, C, D, E, and T) based on viral receptor interference properties or receptor usage. ERV-derived molecules benefit animals, conferring resistance to infectious diseases. However, the soluble protein encoded by the defective envelope (env) gene of endogenous FeLV (enFeLV) functions as a co-factor in FeLV subgroup T infections. Therefore, whether the gene emerged to facilitate viral infection is unclear. Based on the properties of ERV-derived molecules, we hypothesized that the defective env genes possess antiviral activity that would be advantageous to the host because FeLV subgroup B (FeLV-B), a recombinant virus derived from enFeLV env, is restricted to viral transmission among domestic cats. When soluble truncated Env proteins from enFeLV were tested for their inhibitory effects against enFeLV and FeLV-B, they inhibited viral infection. Notably, this antiviral machinery was extended to infection with the Gibbon ape leukemia virus, Koala retrovirus A, and Hervey pteropid gammaretrovirus. Although these viruses used feline phosphate transporter 1 (fePit1) and phosphate transporter 2 as receptors, the inhibitory mechanism involved competitive receptor binding in a fePit1-dependent manner. The shift in receptor usage might have occurred to avoid the inhibitory effect. Overall, these findings highlight the possible emergence of soluble truncated Env proteins from enFeLV as a restriction factor against retroviral infection and will help in developing host immunity and antiviral defense by controlling retroviral spread.IMPORTANCERetroviruses are unique in using reverse transcriptase to convert RNA genomes into DNA, infecting germ cells, and transmitting to offspring. Numerous ancient retroviral sequences are known as endogenous retroviruses (ERVs). The soluble Env protein derived from ERVs functions as a co-factor that assists in FeLV-T infection. However, herein, we show that the soluble Env protein exhibits antiviral activity and provides resistance to mammalian retrovirus infection through competitive receptor binding. In particular, this finding may explain why FeLV-B transmission is not observed among domestic cats. ERV-derived molecules can benefit animals in an evolutionary arms race, highlighting the double-edged-sword nature of ERVs. Endogenous retroviruses (ERVs) are remnants of ancestral viral infections. Feline leukemia virus (FeLV) is an exogenous and endogenous retrovirus in domestic cats. It is classified into several subgroups (A, B, C, D, E, and T) based on viral receptor interference properties or receptor usage. ERV-derived molecules benefit animals, conferring resistance to infectious diseases. However, the soluble protein encoded by the defective envelope (env) gene of endogenous FeLV (enFeLV) functions as a co-factor in FeLV subgroup T infections. Therefore, whether the gene emerged to facilitate viral infection is unclear. Based on the properties of ERV-derived molecules, we hypothesized that the defective env genes possess antiviral activity that would be advantageous to the host because FeLV subgroup B (FeLV-B), a recombinant virus derived from enFeLV env, is restricted to viral transmission among domestic cats. When soluble truncated Env proteins from enFeLV were tested for their inhibitory effects against enFeLV and FeLV-B, they inhibited viral infection. Notably, this antiviral machinery was extended to infection with the Gibbon ape leukemia virus, Koala retrovirus A, and Hervey pteropid gammaretrovirus. Although these viruses used feline phosphate transporter 1 (fePit1) and phosphate transporter 2 as receptors, the inhibitory mechanism involved competitive receptor binding in a fePit1-dependent manner. The shift in receptor usage might have occurred to avoid the inhibitory effect. Overall, these findings highlight the possible emergence of soluble truncated Env proteins from enFeLV as a restriction factor against retroviral infection and will help in developing host immunity and antiviral defense by controlling retroviral spread.IMPORTANCERetroviruses are unique in using reverse transcriptase to convert RNA genomes into DNA, infecting germ cells, and transmitting to offspring. Numerous ancient retroviral sequences are known as endogenous retroviruses (ERVs). The soluble Env protein derived from ERVs functions as a co-factor that assists in FeLV-T infection. However, herein, we show that the soluble Env protein exhibits antiviral activity and provides resistance to mammalian retrovirus infection through competitive receptor binding. In particular, this finding may explain why FeLV-B transmission is not observed among domestic cats. ERV-derived molecules can benefit animals in an evolutionary arms race, highlighting the double-edged-sword nature of ERVs.Endogenous retroviruses (ERVs) are remnants of ancestral viral infections. Feline leukemia virus (FeLV) is an exogenous and endogenous retrovirus in domestic cats. It is classified into several subgroups (A, B, C, D, E, and T) based on viral receptor interference properties or receptor usage. ERV-derived molecules benefit animals, conferring resistance to infectious diseases. However, the soluble protein encoded by the defective envelope (env) gene of endogenous FeLV (enFeLV) functions as a co-factor in FeLV subgroup T infections. Therefore, whether the gene emerged to facilitate viral infection is unclear. Based on the properties of ERV-derived molecules, we hypothesized that the defective env genes possess antiviral activity that would be advantageous to the host because FeLV subgroup B (FeLV-B), a recombinant virus derived from enFeLV env, is restricted to viral transmission among domestic cats. When soluble truncated Env proteins from enFeLV were tested for their inhibitory effects against enFeLV and FeLV-B, they inhibited viral infection. Notably, this antiviral machinery was extended to infection with the Gibbon ape leukemia virus, Koala retrovirus A, and Hervey pteropid gammaretrovirus. Although these viruses used feline phosphate transporter 1 (fePit1) and phosphate transporter 2 as receptors, the inhibitory mechanism involved competitive receptor binding in a fePit1-dependent manner. The shift in receptor usage might have occurred to avoid the inhibitory effect. Overall, these findings highlight the possible emergence of soluble truncated Env proteins from enFeLV as a restriction factor against retroviral infection and will help in developing host immunity and antiviral defense by controlling retroviral spread.IMPORTANCERetroviruses are unique in using reverse transcriptase to convert RNA genomes into DNA, infecting germ cells, and transmitting to offspring. Numerous ancient retroviral sequences are known as endogenous retroviruses (ERVs). The soluble Env protein derived from ERVs functions as a co-factor that assists in FeLV-T infection. However, herein, we show that the soluble Env protein exhibits antiviral activity and provides resistance to mammalian retrovirus infection through competitive receptor binding. In particular, this finding may explain why FeLV-B transmission is not observed among domestic cats. ERV-derived molecules can benefit animals in an evolutionary arms race, highlighting the double-edged-sword nature of ERVs. Retroviruses are unique in using reverse transcriptase to convert RNA genomes into DNA, infecting germ cells, and transmitting to offspring. Numerous ancient retroviral sequences are known as endogenous retroviruses (ERVs). The soluble Env protein derived from ERVs functions as a co-factor that assists in FeLV-T infection. However, herein, we show that the soluble Env protein exhibits antiviral activity and provides resistance to mammalian retrovirus infection through competitive receptor binding. In particular, this finding may explain why FeLV-B transmission is not observed among domestic cats. ERV-derived molecules can benefit animals in an evolutionary arms race, highlighting the double-edged-sword nature of ERVs. |
| Author | Kawasaki, Junna AbuEed, Loai Miyake, Ariko Takeuchi, Dai Katsuki, Masato Kimura, Tohru Nishigaki, Kazuo Pramono, Didik Abdillah, Dimas |
| Author_xml | – sequence: 1 givenname: Didik surname: Pramono fullname: Pramono, Didik organization: Laboratory of Molecular Immunology and Infectious Disease, The Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan, Research Institute for Cell Design Medical Science, Yamaguchi University, Yamaguchi, Japan – sequence: 2 givenname: Dai surname: Takeuchi fullname: Takeuchi, Dai organization: Laboratory of Molecular Immunology and Infectious Disease, The Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan – sequence: 3 givenname: Masato surname: Katsuki fullname: Katsuki, Masato organization: Laboratory of Molecular Immunology and Infectious Disease, The Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan – sequence: 4 givenname: Loai surname: AbuEed fullname: AbuEed, Loai organization: Laboratory of Molecular Immunology and Infectious Disease, The Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan, Research Institute for Cell Design Medical Science, Yamaguchi University, Yamaguchi, Japan – sequence: 5 givenname: Dimas surname: Abdillah fullname: Abdillah, Dimas organization: Laboratory of Molecular Immunology and Infectious Disease, The Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan, Research Institute for Cell Design Medical Science, Yamaguchi University, Yamaguchi, Japan – sequence: 6 givenname: Tohru surname: Kimura fullname: Kimura, Tohru organization: The Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan – sequence: 7 givenname: Junna orcidid: 0000-0002-6609-5300 surname: Kawasaki fullname: Kawasaki, Junna organization: Faculty of Science and Engineering, Waseda University, Tokyo, Japan – sequence: 8 givenname: Ariko surname: Miyake fullname: Miyake, Ariko organization: Laboratory of Molecular Immunology and Infectious Disease, The Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan, Research Institute for Cell Design Medical Science, Yamaguchi University, Yamaguchi, Japan – sequence: 9 givenname: Kazuo orcidid: 0000-0002-7690-2137 surname: Nishigaki fullname: Nishigaki, Kazuo organization: Laboratory of Molecular Immunology and Infectious Disease, The Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan, Research Institute for Cell Design Medical Science, Yamaguchi University, Yamaguchi, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38440982$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkE1LxDAQhoMoun7cPEuPClYz-Wjak8riFyx4UfAWpt1Us7SJJu2C_97oqih4GOYwDw_zvttk3XlnCNkHegLAytPF0p5QUApyxtfIBGhV5lKCWCcTShnLJS8ft8h2jAtKQYhCbJItXgqRODYh51dmdvuY2ZhhFkwcgm0G613WYjP4kLVpeux77Cy6BAzBL20YY2Zdaz7JXbLRYhfN3tfeIQ9Xl_fTm3x2d307vZjlyFUx5E1NmcQSJcrKVPMGJaXzQrWqKJExJeuiRl4JMKAEBdqyCqHlFJGZOoWr-Q45W3lfxro388a4IWCnX4LtMbxpj1b_vTj7rJ_8UgNQqErJk-HwyxD865iy6t7GxnQdOuPHqFnFlaIcQCT0aIVi7Jle-DG4lE0D1R-V61S5_qxcsw_twe_Hfj767jgBxyugCT7GYNof5F_fO57pjTE |
| Cites_doi | 10.3390/v7010001 10.1073/pnas.071432398 10.1002/ijc.2910210314 10.1016/j.virol.2006.09.004 10.1128/JVI.00353-21 10.1101/gr.6380007 10.1073/pnas.1304704110 10.1128/jvi.76.23.12369-12375.2002 10.1128/JVI.00269-19 10.1007/BF02624087 10.1093/nar/gkh340 10.1099/vir.0.071688-0 10.1016/0042-6822(71)90266-2 10.1128/JVI.75.19.8888-8898.2001 10.1126/science.abq7871 10.1016/j.cvsm.2020.05.006 10.1016/s0167-4781(98)00241-3 10.1073/pnas.1915400117 10.1128/JVI.80.7.3378-3385.2006 10.1128/JVI.68.4.2151-2160.1994 10.1128/JVI.73.8.6500-6505.1999 10.1038/newbio235170a0 10.1128/MMBR.00044-17 10.1007/BF02618435 10.1093/molbev/msab120 10.1128/JVI.71.11.8116-8123.1997 10.1007/BF01320971 10.1128/JVI.55.3.768-777.1985 10.1128/JVI.66.2.1219-1222.1992 10.1128/JVI.73.10.7994-8002.1999 10.1093/bioinformatics/12.6.543 10.1038/srep08164 10.1128/JVI.00716-16 10.1128/JVI.01267-13 10.1128/jvi.00684-23 10.1128/JVI.52.2.695-698.1984 10.1128/jvi.76.3.1527-1532.2002 10.1128/JVI.02317-08 10.1128/JVI.03229-15 10.1038/332731a0 10.1128/JVI.00280-12 10.1093/oso/9780195135848.001.0001 10.1128/JVI.65.5.2220-2224.1991 10.1111/j.1749-6632.2009.05002.x 10.1128/JVI.75.22.10563-10572.2001 10.1128/JVI.01324-19 10.1016/j.vetimm.2010.12.010 10.1016/0168-9525(91)90017-k 10.3201/eid2501.181347 10.1128/jvi.77.4.2717-2729.2003 10.1128/JVI.60.1.242-250.1986 10.1038/382826a0 10.1371/journal.pone.0061009 10.1128/JVI.00070-21 10.1016/j.jmb.2021.167421 10.1093/oxfordjournals.molbev.a025763 10.1007/BF01731581 10.1016/j.cell.2020.04.004 10.1016/0042-6822(73)90125-6 10.1128/JVI.80.6.3104-3107.2006 10.1084/jem.108.6.945 10.1038/35057062 10.1128/JVI.61.1.8-15.1987 10.1099/0022-1317-36-1-59 10.1006/viro.1995.0069 10.1126/science.287.5459.1828 10.1182/blood.V95.3.1093.003k01_1093_1099 10.1126/science.2893454 10.1073/pnas.2122680119 10.1073/pnas.2114441119 10.1038/nature01262 10.1002/ijc.24050 10.1006/viro.2000.0606 10.1128/JVI.72.4.2686-2696.1998 10.1038/275656a0 10.1128/JVI.63.5.2379-2384.1989 |
| ContentType | Journal Article |
| Copyright | Copyright © 2024 Pramono et al. Copyright © 2024 Pramono et al. 2024 Pramono et al. |
| Copyright_xml | – notice: Copyright © 2024 Pramono et al. – notice: Copyright © 2024 Pramono et al. 2024 Pramono et al. |
| DBID | AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.1128/jvi.01771-23 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1098-5514 |
| Editor | Simon, Viviana |
| Editor_xml | – sequence: 1 givenname: Viviana surname: Simon fullname: Simon, Viviana |
| ExternalDocumentID | PMC11019853 01771-23 38440982 10_1128_jvi_01771_23 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: KAKENHI grantid: 20H03152, 23H02393 – fundername: ; grantid: 20H03152, 23H02393 |
| GroupedDBID | --- -~X 0R~ 18M 29L 2WC 39C 4.4 53G 5GY 5RE 5VS 85S AAFWJ AAGFI AAYXX ABPPZ ACGFO ACNCT ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CITATION CS3 DIK E3Z EBS F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 N9A O9- OK1 P2P RHI RNS RPM RSF TR2 UPT W2D W8F WH7 WOQ YQT ~02 ~KM NPM RHF UCJ ZA5 7X8 5PM |
| ID | FETCH-LOGICAL-a376t-cb025a8a5a59e9dca500d67f768a2275b6ba3941e174010f29a1f30aa2eb177b3 |
| ISSN | 0022-538X 1098-5514 |
| IngestDate | Thu Aug 21 18:34:11 EDT 2025 Thu Jul 10 19:58:20 EDT 2025 Tue Apr 16 18:40:28 EDT 2024 Mon Jul 21 05:13:25 EDT 2025 Tue Jul 01 01:32:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | restriction factor endogenous retrovirus feline leukemia virus |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-a376t-cb025a8a5a59e9dca500d67f768a2275b6ba3941e174010f29a1f30aa2eb177b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The authors declare no conflict of interest. |
| ORCID | 0000-0002-6609-5300 0000-0002-7690-2137 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC11019853 |
| PMID | 38440982 |
| PQID | 2937703114 |
| PQPubID | 23479 |
| PageCount | 23 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11019853 proquest_miscellaneous_2937703114 asm2_journals_10_1128_jvi_01771_23 pubmed_primary_38440982 crossref_primary_10_1128_jvi_01771_23 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-04-16 |
| PublicationDateYYYYMMDD | 2024-04-16 |
| PublicationDate_xml | – month: 04 year: 2024 text: 2024-04-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Journal of virology |
| PublicationTitleAbbrev | J Virol |
| PublicationTitleAlternate | J Virol |
| PublicationYear | 2024 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_5_27_2 e_1_3_5_25_2 e_1_3_5_23_2 e_1_3_5_21_2 e_1_3_5_44_2 e_1_3_5_65_2 e_1_3_5_46_2 e_1_3_5_67_2 e_1_3_5_48_2 e_1_3_5_69_2 e_1_3_5_29_2 Soltis RD (e_1_3_5_52_2) 1979; 36 e_1_3_5_82_2 e_1_3_5_80_2 e_1_3_5_40_2 e_1_3_5_61_2 e_1_3_5_42_2 e_1_3_5_63_2 e_1_3_5_7_2 e_1_3_5_9_2 e_1_3_5_3_2 e_1_3_5_5_2 Rasheed S (e_1_3_5_66_2) 1980 e_1_3_5_39_2 e_1_3_5_16_2 e_1_3_5_37_2 e_1_3_5_14_2 e_1_3_5_12_2 e_1_3_5_35_2 Hall TA (e_1_3_5_77_2) 1999 e_1_3_5_10_2 e_1_3_5_33_2 e_1_3_5_54_2 e_1_3_5_56_2 e_1_3_5_79_2 e_1_3_5_58_2 e_1_3_5_18_2 e_1_3_5_71_2 e_1_3_5_50_2 e_1_3_5_73_2 e_1_3_5_75_2 e_1_3_5_31_2 e_1_3_5_28_2 e_1_3_5_26_2 e_1_3_5_24_2 e_1_3_5_22_2 e_1_3_5_45_2 e_1_3_5_68_2 Coffin JM (e_1_3_5_2_2) 1997 e_1_3_5_47_2 e_1_3_5_49_2 e_1_3_5_81_2 e_1_3_5_60_2 e_1_3_5_62_2 e_1_3_5_41_2 e_1_3_5_64_2 e_1_3_5_8_2 e_1_3_5_20_2 e_1_3_5_4_2 e_1_3_5_6_2 e_1_3_5_17_2 O’Hara B (e_1_3_5_43_2) 1990; 1 e_1_3_5_38_2 e_1_3_5_15_2 e_1_3_5_36_2 e_1_3_5_13_2 e_1_3_5_34_2 e_1_3_5_11_2 e_1_3_5_32_2 e_1_3_5_55_2 e_1_3_5_76_2 e_1_3_5_57_2 e_1_3_5_78_2 e_1_3_5_59_2 e_1_3_5_19_2 e_1_3_5_70_2 e_1_3_5_51_2 e_1_3_5_72_2 e_1_3_5_53_2 e_1_3_5_74_2 e_1_3_5_30_2 |
| References_xml | – ident: e_1_3_5_10_2 doi: 10.3390/v7010001 – ident: e_1_3_5_51_2 doi: 10.1073/pnas.071432398 – ident: e_1_3_5_13_2 doi: 10.1002/ijc.2910210314 – ident: e_1_3_5_33_2 doi: 10.1016/j.virol.2006.09.004 – volume-title: Bioedit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT year: 1999 ident: e_1_3_5_77_2 – ident: e_1_3_5_28_2 doi: 10.1128/JVI.00353-21 – ident: e_1_3_5_5_2 doi: 10.1101/gr.6380007 – ident: e_1_3_5_45_2 doi: 10.1073/pnas.1304704110 – ident: e_1_3_5_50_2 doi: 10.1128/jvi.76.23.12369-12375.2002 – ident: e_1_3_5_20_2 doi: 10.1128/JVI.00269-19 – volume: 1 start-page: 119 year: 1990 ident: e_1_3_5_43_2 article-title: Characterization of a human gene conferring sensitivity to infection by gibbon ape leukemia virus publication-title: Cell Growth Differ – ident: e_1_3_5_74_2 doi: 10.1007/BF02624087 – ident: e_1_3_5_79_2 doi: 10.1093/nar/gkh340 – ident: e_1_3_5_34_2 doi: 10.1099/vir.0.071688-0 – ident: e_1_3_5_16_2 doi: 10.1016/0042-6822(71)90266-2 – volume-title: Proceedings of the third International feline leukemia virus meeting year: 1980 ident: e_1_3_5_66_2 – volume-title: Retroviruses year: 1997 ident: e_1_3_5_2_2 – ident: e_1_3_5_32_2 doi: 10.1128/JVI.75.19.8888-8898.2001 – ident: e_1_3_5_7_2 doi: 10.1126/science.abq7871 – ident: e_1_3_5_15_2 doi: 10.1016/j.cvsm.2020.05.006 – ident: e_1_3_5_41_2 doi: 10.1016/s0167-4781(98)00241-3 – ident: e_1_3_5_46_2 doi: 10.1073/pnas.1915400117 – ident: e_1_3_5_19_2 doi: 10.1128/JVI.80.7.3378-3385.2006 – ident: e_1_3_5_38_2 doi: 10.1128/JVI.68.4.2151-2160.1994 – ident: e_1_3_5_24_2 doi: 10.1128/JVI.73.8.6500-6505.1999 – ident: e_1_3_5_47_2 doi: 10.1038/newbio235170a0 – ident: e_1_3_5_31_2 doi: 10.1128/MMBR.00044-17 – ident: e_1_3_5_67_2 doi: 10.1007/BF02618435 – ident: e_1_3_5_78_2 doi: 10.1093/molbev/msab120 – ident: e_1_3_5_30_2 doi: 10.1128/JVI.71.11.8116-8123.1997 – ident: e_1_3_5_54_2 doi: 10.1007/BF01320971 – ident: e_1_3_5_9_2 doi: 10.1128/JVI.55.3.768-777.1985 – ident: e_1_3_5_25_2 doi: 10.1128/JVI.66.2.1219-1222.1992 – ident: e_1_3_5_56_2 doi: 10.1128/JVI.73.10.7994-8002.1999 – ident: e_1_3_5_76_2 doi: 10.1093/bioinformatics/12.6.543 – ident: e_1_3_5_55_2 doi: 10.1038/srep08164 – ident: e_1_3_5_69_2 doi: 10.1128/JVI.00716-16 – ident: e_1_3_5_8_2 doi: 10.1128/JVI.01267-13 – ident: e_1_3_5_61_2 doi: 10.1128/jvi.00684-23 – ident: e_1_3_5_64_2 doi: 10.1128/JVI.52.2.695-698.1984 – ident: e_1_3_5_70_2 doi: 10.1128/jvi.76.3.1527-1532.2002 – ident: e_1_3_5_23_2 doi: 10.1128/JVI.02317-08 – ident: e_1_3_5_72_2 doi: 10.1128/JVI.03229-15 – ident: e_1_3_5_26_2 doi: 10.1038/332731a0 – ident: e_1_3_5_53_2 doi: 10.1128/JVI.00280-12 – ident: e_1_3_5_80_2 doi: 10.1093/oso/9780195135848.001.0001 – ident: e_1_3_5_73_2 doi: 10.1128/JVI.65.5.2220-2224.1991 – ident: e_1_3_5_11_2 doi: 10.1111/j.1749-6632.2009.05002.x – ident: e_1_3_5_18_2 doi: 10.1128/JVI.75.22.10563-10572.2001 – ident: e_1_3_5_62_2 doi: 10.1128/JVI.01324-19 – ident: e_1_3_5_75_2 doi: 10.1016/j.vetimm.2010.12.010 – ident: e_1_3_5_12_2 doi: 10.1016/0168-9525(91)90017-k – ident: e_1_3_5_37_2 doi: 10.3201/eid2501.181347 – ident: e_1_3_5_42_2 doi: 10.1128/jvi.77.4.2717-2729.2003 – ident: e_1_3_5_71_2 doi: 10.1128/JVI.60.1.242-250.1986 – ident: e_1_3_5_57_2 doi: 10.1038/382826a0 – ident: e_1_3_5_27_2 doi: 10.1371/journal.pone.0061009 – ident: e_1_3_5_39_2 doi: 10.1128/JVI.00070-21 – ident: e_1_3_5_58_2 doi: 10.1016/j.jmb.2021.167421 – ident: e_1_3_5_81_2 doi: 10.1093/oxfordjournals.molbev.a025763 – volume: 36 start-page: 37 year: 1979 ident: e_1_3_5_52_2 article-title: The effect of heat inactivation of serum on aggregation of immunoglobulins publication-title: Immunology – ident: e_1_3_5_82_2 doi: 10.1007/BF01731581 – ident: e_1_3_5_60_2 doi: 10.1016/j.cell.2020.04.004 – ident: e_1_3_5_22_2 doi: 10.1016/0042-6822(73)90125-6 – ident: e_1_3_5_44_2 doi: 10.1128/JVI.80.6.3104-3107.2006 – ident: e_1_3_5_65_2 doi: 10.1084/jem.108.6.945 – ident: e_1_3_5_3_2 doi: 10.1038/35057062 – ident: e_1_3_5_48_2 doi: 10.1128/JVI.61.1.8-15.1987 – ident: e_1_3_5_63_2 doi: 10.1099/0022-1317-36-1-59 – ident: e_1_3_5_49_2 doi: 10.1006/viro.1995.0069 – ident: e_1_3_5_17_2 doi: 10.1126/science.287.5459.1828 – ident: e_1_3_5_21_2 doi: 10.1182/blood.V95.3.1093.003k01_1093_1099 – ident: e_1_3_5_36_2 doi: 10.1126/science.2893454 – ident: e_1_3_5_59_2 doi: 10.1073/pnas.2122680119 – ident: e_1_3_5_6_2 doi: 10.1073/pnas.2114441119 – ident: e_1_3_5_4_2 doi: 10.1038/nature01262 – ident: e_1_3_5_14_2 doi: 10.1002/ijc.24050 – ident: e_1_3_5_29_2 doi: 10.1006/viro.2000.0606 – ident: e_1_3_5_35_2 doi: 10.1128/JVI.72.4.2686-2696.1998 – ident: e_1_3_5_68_2 doi: 10.1038/275656a0 – ident: e_1_3_5_40_2 doi: 10.1128/JVI.63.5.2379-2384.1989 |
| SSID | ssj0014464 |
| Score | 2.4526253 |
| Snippet | Retroviruses are unique in using reverse transcriptase to convert RNA genomes into DNA, infecting germ cells, and transmitting to offspring. Numerous ancient... Endogenous retroviruses (ERVs) are remnants of ancestral viral infections. Feline leukemia virus (FeLV) is an exogenous and endogenous retrovirus in domestic... |
| SourceID | pubmedcentral proquest asm2 pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | e0177123 |
| SubjectTerms | Veterinary Microbiology Virus-Cell Interactions |
| Title | FeLIX is a restriction factor for mammalian retrovirus infection |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38440982 https://journals.asm.org/doi/10.1128/jvi.01771-23 https://www.proquest.com/docview/2937703114 https://pubmed.ncbi.nlm.nih.gov/PMC11019853 |
| Volume | 98 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKEagXBOVrW4oMghNKWTveJL4V0VYtbRGHrbS3aJx1REDJVvmoBL-esZ1ksy0rFS7RKvEm0jxn8mbsmUfIu0QEqUoC5knJEw-9ZOApgTGPEsk4BK6R05sV3Yuvwcml-DKbzDqF7La6pFb7ye-_1pX8D6p4DnE1VbL_gGx_UzyBvxFfPCLCeLwTxsf6_HRmJMnhg5HYKDOn--00dOwGwhzy3GUySl2b7EHZLDdgFWuYqSl9Gybbv5VGksjmVA-zedbX9kzhpzZaKm5vfNb7bqirxqlhX0CFQf1yiak5crnV80U7vM03cLtNhbXdqp2PNC1IDdEa-D2NL3bIXOXwbafMTaHBj-ts347yVoehSa9yC5AfCYw2nRbRjSbY3aV75D7HeMDGzqdn_XIRxrSiq2rg0cfho7bIw-7P-NWFKuerDORWWHFzd-yAbkwfk0ctGvSTA_0J2dDFNnnglEN_PSUHFnqaVRToAHrqoKcIPe2hp0voaQ_9M3J5fDT9fOK1Yhge4Deg9hKF7BQimMBEajm3ShbzIEwxXATOw4kKFPhSMM2MxuI45RJY6o8B3zfTYUz5z8lmsSj0S0J9iaxYAqQShFAYUjKdBEglI2SjkKZ6RN4aO8XtTK9iGyjyKEa7xtauMfdH5H1nxfjKNUZZM-5NZ-IYPZdZjoJCL5oqRqIZGvUEJkbkhTN5f6cOshGJVsDoB5iu6KtXiuy77Y6OfJZJJKE7a2-6S7aWE_sV2azLRu8htazVazut_gCMDXeT |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FeLIX+is+a+restriction+factor+for+mammalian+retrovirus+infection&rft.jtitle=Journal+of+virology&rft.au=Pramono%2C+Didik&rft.au=Takeuchi%2C+Dai&rft.au=Katsuki%2C+Masato&rft.au=AbuEed%2C+Loai&rft.date=2024-04-16&rft.eissn=1098-5514&rft.spage=e0177123&rft_id=info:doi/10.1128%2Fjvi.01771-23&rft_id=info%3Apmid%2F38440982&rft.externalDocID=38440982 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon |